Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

[1]  A. Hauschild,et al.  Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. , 2015, The Lancet. Oncology.

[2]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[3]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[4]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[5]  A. Ribas,et al.  Anti-PD-1 therapy in melanoma. , 2015, Seminars in oncology.

[6]  D. Schadendorf,et al.  Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. , 2015, European journal of cancer.

[7]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[8]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[9]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[10]  D. Schadendorf,et al.  Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  D. Osoba,et al.  A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites , 2014, Cancer.

[12]  M. Atkins,et al.  PD-1 as a potential target in cancer therapy , 2013, Cancer medicine.

[13]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[14]  Ali Montazeri,et al.  Health and Quality of Life Outcomes , 2009 .

[15]  J. Allison,et al.  Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.

[16]  M. Middleton,et al.  Health-Related Quality of Life in Patients with Advanced Metastatic Melanoma: Results of a Randomized Phase III Study Comparing Temozolomide with Dacarbazine , 2003, Cancer investigation.

[17]  G. Freeman,et al.  PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 , 2002, European journal of immunology.

[18]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[19]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[20]  J. Cormier,et al.  Assessment of patient-reported outcomes in patients with melanoma. , 2011, Surgical oncology clinics of North America.

[21]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.